Skip to main content
Fig. 2 | BMC Health Services Research

Fig. 2

From: Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences

Fig. 2

a One-way Sensitivity Analysis versus Initial LMWH/VKA. b One-way Sensitivity Analysis versus Initial plus Extended LMWH/VKA. The tornado diagrams (Fig. 2a and b) present the results of the deterministic sensitivity analyses and depict the key parameters that had the greatest impact on the ICER. The boxes to the right and left of the tornado diagram represent the range tested for the parameter detailed in the description. *The variation in the unit cost associated with apixaban corresponds to a range of the daily cost associated with apixaban of £3.07-£5.71 in the initial period and £1.54-£2.85 in the prolonged and extended period

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us